Fig. 3: Low-dose TM preconditioning partially interferes with LLO biosynthesis and N-glycan assembly.
A HPLC profiles and cellular levels of LLO glycans. Low-HA Has2+Neo cells were treated with 0.1 or 0.2 μg/ml TM for 8 days and analyzed for cellular LLO levels. Data are the mean ± SD from n = 3. Tukey’s test. *p < 0.05, **p < 0.01. B N-glycan composition of TM-treated and untreated cells. Low-HA Has2+Neo cells were treated with 0.1 or 0.2 μg/ml TM for 8 days and analyzed for N-glycan compositions. N-glycan composition is expressed as the ratio of each glycan type to the total N-glycans. C Relative amounts of PM, HM, and C/H-type N-glycans. The colors representing each glycoform are listed in Supplementary Table S2. Data are the mean ± SD from n = 3. Two-tailed Student’s t-test. *p < 0.05, **p < 0.01. D Hierarchical clustering analysis based on the quantitative glycomic profiles of N-glycans. The hierarchical clustering heatmap represents the normalized abundance of N-glycans in the TM-treated and untreated cells. The Neu, Has2+Neo, and Has2ΔNeo cell datasets were reused from Fig. 1D. The complete structures of the N-glycans are shown in Supplementary Tables S1 and S2. The bars on the right side of the heatmap indicate N-glycan modifications. Selected glycan structures are shown on the right, with important modifications (red circles).
